These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 39033271)
1. Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer. Hu Y; Lou X; Zhang K; Pan L; Bai Y; Wang L; Wang M; Yan Y; Wan J; Yao X; Duan X; Ni C; Qin Z J Transl Med; 2024 Jul; 22(1):672. PubMed ID: 39033271 [TBL] [Abstract][Full Text] [Related]
2. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors. Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A Cells; 2021 Jun; 10(6):. PubMed ID: 34201054 [TBL] [Abstract][Full Text] [Related]
3. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer. Zhao Y; Yu Y; Li X; Guo A J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816 [TBL] [Abstract][Full Text] [Related]
4. Scutellarin suppresses the metastasis of triple-negative breast cancer via targeting TNFα/TNFR2-RUNX1-triggered G-CSF expression in endothelial cells. Mei X; Ouyang H; Zhang H; Jia W; Lu B; Zhang J; Ji L Biochem Pharmacol; 2023 Nov; 217():115808. PubMed ID: 37716622 [TBL] [Abstract][Full Text] [Related]
5. TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients. Dadiani M; Necula D; Kahana-Edwin S; Oren N; Baram T; Marin I; Morzaev-Sulzbach D; Pavlovski A; Balint-Lahat N; Anafi L; Wiemann S; Korner C; Gal-Yam EN; Avivi C; Kaufman B; Barshack I; Ben-Baruch A Cancer Immunol Immunother; 2020 Jul; 69(7):1315-1326. PubMed ID: 32198536 [TBL] [Abstract][Full Text] [Related]
6. Novel insights into paclitaxel's role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment. Choi Y; Kim SA; Jung H; Kim E; Kim YK; Kim S; Kim J; Lee Y; Jo MK; Woo J; Cho Y; Lee D; Choi H; Jeong C; Nam GH; Kwon M; Kim IS J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39009452 [TBL] [Abstract][Full Text] [Related]
7. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434 [TBL] [Abstract][Full Text] [Related]
8. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer. Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272 [No Abstract] [Full Text] [Related]
9. Intratumoral Plasmid IL12 Expands CD8 Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880 [TBL] [Abstract][Full Text] [Related]
10. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells. Twu YC; Gold MR; Teh HS Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004 [TBL] [Abstract][Full Text] [Related]
11. Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis. Punit S; Dubé PE; Liu CY; Girish N; Washington MK; Polk DB Gastroenterology; 2015 Oct; 149(4):993-1005.e2. PubMed ID: 26072395 [TBL] [Abstract][Full Text] [Related]
12. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748 [TBL] [Abstract][Full Text] [Related]
13. Both internalization and AIP1 association are required for tumor necrosis factor receptor 2-mediated JNK signaling. Ji W; Li Y; Wan T; Wang J; Zhang H; Chen H; Min W Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2271-9. PubMed ID: 22743059 [TBL] [Abstract][Full Text] [Related]
14. IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Xia J; Zhang L; Peng X; Tu J; Li S; He X; Li F; Qiang J; Dong H; Deng Q; Liu C; Xu J; Zhang R; Liu Q; Hu G; Liu C; Jiang YZ; Shao ZM; Chen C; Liu S Cancer Res; 2024 Jul; 84(14):2282-2296. PubMed ID: 38657120 [TBL] [Abstract][Full Text] [Related]
15. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190 [TBL] [Abstract][Full Text] [Related]
16. Eribulin promotes proliferation of CD8 Shimizu T; Oba T; Oshi M; Ito KI Breast Cancer Res Treat; 2024 Jan; 203(1):57-71. PubMed ID: 37733186 [TBL] [Abstract][Full Text] [Related]
17. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity. Chen Y; Jia M; Wang S; Xu S; He N Front Immunol; 2022; 13():835690. PubMed ID: 35251028 [TBL] [Abstract][Full Text] [Related]
18. Baohuoside I chemosensitises breast cancer to paclitaxel by suppressing extracellular vesicle/CXCL1 signal released from apoptotic cells. Wang S; Li J; Xu S; Wang N; Pan B; Yang B; Zheng Y; Zhang J; Peng F; Peng C; Wang Z J Extracell Vesicles; 2024 Jul; 13(7):e12493. PubMed ID: 39051750 [TBL] [Abstract][Full Text] [Related]
19. Cancer cell-derived exosomal miR-20a-5p inhibits CD8 Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137 [TBL] [Abstract][Full Text] [Related]
20. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment. Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]